Switch to
View more

Glenmark Life Sciences Ltd

GLS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,393 cr, stock is ranked 489
Low RiskStock is 1.49x as volatile as Nifty
440.203.70 (-0.83%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,393 cr, stock is ranked 489
Low RiskStock is 1.49x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
12.88
PB RatioPB Ratio
7.17
Dividend YieldDiv. Yield
4.20%
Sector PESector PE
34.62
Sector PBSector PB
4.37
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.

Investor PresentationView older 

Aug 4, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120220.891.551.892.140.200.310.350.42
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Monitoring Agency Report 
Announced OnAug 12, 2022

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th June, 2022 in respect of utilization of proceeds of the IPO of the Company. | Download

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th June, 2022 in respect of utilization of proceeds of the IPO of the Company. | Download

Transcript of Analysts/Institutional Investor Meet/Con. Call 
Announced OnAug 8, 2022

Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, 5th August, 2022 for the quarter ended June 30, 2022 is available on the Company¬タルs website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q1%20FY2022-23.pdf | Download

Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, 5th August, 2022 for the quarter ended June 30, 2022 is available on the Company¬タルs website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q1%20FY2022-23.pdf | Download

Cash Dividend 
Ex. DateNov 22, 2021

Interim • Div/Share: ₹ 10.5

See all events